News | March 19, 2026
Alcon walks away from LENSAR deal after regulatory roadblock
At the center of the collapse is opposition from the Federal Trade Commission
At the center of the collapse is opposition from the Federal Trade Commission
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
It is the first presbyopia-correcting lens implant for cataract surgery
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
Subscribe To Our Newsletter & Stay Updated
